Abstract

Central nervous system (CNS) infections are associated with high mortality rates, morbidity, limited antibiotic treatment options, and high cost of therapy especially in low and middle-income countries. Post-neurosurgical infections are often associated with multi-drug resistant organisms. Given the limited options of antibiotics due to blood-brain and blood-cerebrospinal fluid (CSF) barriers, exploring various antibiotic combinations including the latest ones is imperative. Drugs like Ceftazidime- Avibactam and Aztreonam may be useful in carbapenem-resistant gram-negative infections. More robust studies may be designed to offer better treatment options for difficult CNS infections.